Clinical Trials

4 results for Kidney/Renal Cancer


PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

  • Condition: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in Lymph Node, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Malignant Neoplasm in the Viscera, Sarcomatoid Renal Cell Carcinoma
  • Study ID: NCT03793166
View Trial

Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Axitinib, Drug: Avelumab
  • Study ID: NCT03341845
View Trial

A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)

  • Condition: Carcinoma, Renal Cell
  • Intervention: Drug: Spartalizumab, Drug: Canakinumab
  • Study ID: NCT04028245
View Trial

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Neph

  • Condition: Clear Cell Renal Cell Carcinoma
  • Study ID: NCT05239728
View Trial